CLCS

Cell Source, Inc.

Price Chart

Latest Quote

$0.83

+0.06 (+7.79%)

Current Price

Previous Close	$0.77
Open	$0.83
Day High	$0.83
Day Low	$0.83
Volume	200

Fetched: 2026-06-18T01:42:56

Stock Information

Shares Outstanding	67.95M
Total Debt	$10.82M
Cash Equivalents	$1K
Net Income	$-6.12M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$56.40M
EPS (TTM)	$-0.14
Exchange	PNK

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$63.14M
Income	$-6.12M
Book/sh	$-0.45
Cash/sh	$0.00
Employees	1

Financial Ratios

Current Ratio

0.01

Returns & Margins

ROA

-1233.46%

Ownership

Insider Ownership	19.68%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-1.86

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$0.81
SMA50	$0.82
SMA200	$0.65
RSI	55.17
ATR	0.0308

Volatility	-197.70
Rel Volume	0.17

Performance History

Week	+1.22%
Month	+1.22%
Quarter	-5.68%
6 Months	+124.89%
YTD	+66.00%
Year	+178.76%
3 Years	+207400.00%
5 Years	-56.32%
10 Years	-16.16%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$0.83	200
2026-06-16	$0.77	4,261
2026-06-15	$0.82	1,800
2026-06-12	$0.82	250
2026-06-11	$0.77	182
2026-06-10	$0.82	600
2026-06-09	$0.82	0
2026-06-08	$0.82	200
2026-06-05	$0.82	750
2026-06-04	$0.80	0
2026-06-03	$0.80	425
2026-06-02	$0.77	959
2026-06-01	$0.80	0
2026-05-29	$0.80	0
2026-05-28	$0.80	9,462
2026-05-27	$0.80	403
2026-05-26	$0.83	353
2026-05-22	$0.82	4,348
2026-05-21	$0.84	0
2026-05-20	$0.84	0
2026-05-19	$0.84	18,675
2026-05-18	$0.82	0

About Cell Source, Inc.

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.

📰 Latest News

No news articles available at the moment. Check back later for updates on CLCS.

Period:

Income Statement (Annual)

Metric	2023-12-31	2022-12-31	2021-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Interest Expense	$1,048,686	$992,415	$1,360,703
Total Expenses	$4,182,746	$4,175,333	$4,018,572
Other Income Expense	$-89,780	-	$-93,160
Net Non Operating Interest Income Expense	$-1,048,686	$-992,415	$-1,360,703
Interest Expense Non Operating	$1,048,686	$992,415	$1,360,703
Operating Expense	$4,182,746	$4,175,333	$4,018,572
General And Administrative Expense	$2,604,751	$2,179,160	$2,695,164
Other Non Operating Income Expenses	-	-	$49,983
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-5,321,212	$-5,167,748	$-5,472,435
Net Interest Income	$-1,048,686	$-992,415	$-1,360,703
Normalized Income	$-5,231,432	$-5,167,748	$-5,379,275
Net Income From Continuing And Discontinued Operation	$-5,321,212	$-5,167,748	$-5,472,435
Total Operating Income As Reported	$-4,325,346	$-4,175,333	$-4,018,572
Net Income Common Stockholders	$-6,549,897	$-6,325,234	$-6,445,640
Net Income	$-5,321,212	$-5,167,748	$-5,472,435
Net Income Including Noncontrolling Interests	$-5,321,212	$-5,167,748	$-5,472,435
Net Income Continuous Operations	$-5,321,212	$-5,167,748	$-5,472,435
Pretax Income	$-5,321,212	$-5,167,748	$-5,472,435
Special Income Charges	$-100,680	$0	$-93,160
Operating Income	$-4,182,746	$-4,175,333	$-4,018,572
Per Share
Diluted EPS	$-0.17	$-0.18	$-0.19
Basic EPS	$-0.17	$-0.18	$-0.19
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-4,182,746	$-4,175,333	$-4,018,572
Total Unusual Items	$-89,780	$0	$-93,160
Total Unusual Items Excluding Goodwill	$-89,780	$0	$-93,160
EBITDA (Bullshit earnings)	$-4,272,526	$-4,175,333	$-4,111,732
EBIT	$-4,272,526	$-4,175,333	$-4,111,732
Diluted Average Shares	$37,786,410	$34,836,169	$33,116,729
Basic Average Shares	$37,786,410	$34,836,169	$33,116,729
Diluted NI Availto Com Stockholders	$-6,549,897	$-6,325,234	$-6,445,640
Preferred Stock Dividends	$1,228,685	$1,157,486	$973,205
Other Special Charges	$100,680	-	$93,160
Gain On Sale Of Security	$10,900	-	-
Research And Development	$1,577,995	$1,996,173	$1,323,408
Selling General And Administration	$2,604,751	$2,179,160	$2,695,164
Other Gand A	$2,604,751	$2,179,160	$2,695,164

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2023-12-31	2022-12-31	2021-12-31
Assets
Net Tangible Assets	$-15,611,543	$-12,633,895	$-9,826,135
Total Assets	$195,171	$409,845	$313,767
Total Non Current Assets	$0	$0	$0
Current Assets	$195,171	$409,845	$313,767
Other Current Assets	$12,218	$23,005	$16,922
Prepaid Assets	$160,750	$164,175	$203,750
Cash Cash Equivalents And Short Term Investments	$22,203	$222,665	$93,095
Cash And Cash Equivalents	$22,203	$222,665	$93,095
Cash Financial	$22,203	$222,665	$93,095
Debt
Net Debt	$9,231,971	$7,681,542	$6,376,263
Total Debt	$9,254,174	$7,904,207	$6,469,358
Current Debt And Capital Lease Obligation	$9,254,174	$7,904,207	$6,469,358
Current Debt	$9,254,174	$7,904,207	$6,469,358
Other Current Borrowings	$8,393,857	$6,986,081	$5,559,446
Liabilities
Total Liabilities Net Minority Interest	$15,806,714	$13,043,740	$10,139,902
Total Non Current Liabilities Net Minority Interest	$0	$0	$0
Current Liabilities	$15,806,714	$13,043,740	$10,139,902
Other Current Liabilities	$81,361	$8,237	$36,703
Current Notes Payable	$860,317	$918,126	$909,912
Payables And Accrued Expenses	$5,767,983	$4,496,492	$3,080,237
Interest Payable	$2,419,666	$1,796,736	$1,182,225
Payables	$1,860,207	$1,048,505	$649,988
Other Payable	$135,000	$135,000	$135,000
Dividends Payable	$25,540	$5,217	$67,229
Total Tax Payable	$132,615	$127,963	$124,718
Accounts Payable	$1,467,052	$680,325	$223,041
Equity
Common Stock Equity	$-15,613,529	$-12,635,740	$-9,827,749
Preferred Stock Equity	$1,986	$1,845	$1,614
Total Equity Gross Minority Interest	$-15,611,543	$-12,633,895	$-9,826,135
Stockholders Equity	$-15,611,543	$-12,633,895	$-9,826,135
Retained Earnings	$-41,667,388	$-36,346,176	$-31,178,428
Other
Ordinary Shares Number	$39,830,802	$36,081,758	$34,360,546
Share Issued	$39,830,802	$36,081,758	$34,360,546
Tangible Book Value	$-15,613,529	$-12,635,740	$-9,827,749
Invested Capital	$-6,359,355	$-4,731,533	$-3,358,391
Working Capital	$-15,611,543	$-12,633,895	$-9,826,135
Total Capitalization	$-15,611,543	$-12,633,895	$-9,826,135
Additional Paid In Capital	$26,014,028	$23,674,354	$21,316,318
Capital Stock	$41,817	$37,927	$35,975
Common Stock	$39,831	$36,082	$34,361
Preferred Stock	$1,986	$1,845	$1,614
Pensionand Other Post Retirement Benefit Plans Current	$703,196	$634,804	$553,604
Current Accrued Expenses	$3,907,776	$3,447,987	$2,430,249
Dueto Related Parties Current	$100,000	$100,000	$100,000

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow
Free Cash Flow	$-2,347,891	$-3,138,686	$-3,378,682
Operating Activities
Operating Cash Flow	$-2,347,891	$-3,138,686	$-3,378,682
Cash Flow From Continuing Operating Activities	$-2,347,891	$-3,138,686	$-3,378,682
Operating Gains Losses	$-52,820	-	$172,143
Financing Activities
Issuance Of Capital Stock	$799,918	$0	$0
Financing Cash Flow	$2,147,429	$3,268,256	$3,226,658
Cash Flow From Continuing Financing Activities	$2,147,429	$3,268,256	$3,226,658
Net Other Financing Charges	$-279,467	$-27,926	$-353,074
Net Preferred Stock Issuance	$799,918	$0	$0
Preferred Stock Issuance	$799,918	$0	$0
Other
Repayment Of Debt	$0	$-146,912	$-328,088
Issuance Of Debt	$1,626,978	$3,443,094	$3,907,820
Interest Paid Supplemental Data	$0	$0	$0
Income Tax Paid Supplemental Data	$949	$19,898	$20,768
End Cash Position	$22,203	$222,665	$93,095
Beginning Cash Position	$222,665	$93,095	$245,119
Changes In Cash	$-200,462	$129,570	$-152,024
Net Issuance Payments Of Debt	$1,626,978	$3,296,182	$3,579,732
Net Short Term Debt Issuance	$1,626,978	$3,296,182	-
Short Term Debt Payments	$0	$-146,912	-
Short Term Debt Issuance	$1,626,978	$3,443,094	-
Change In Working Capital	$2,218,487	$1,563,520	$701,240
Change In Other Current Assets	$10,787	$-6,083	$12,729
Change In Payables And Accrued Expense	$1,882,775	$1,530,028	$394,192
Change In Accrued Expense	$1,096,048	$1,072,744	$364,246
Change In Interest Payable	$812,917	$583,527	$481,214
Change In Payable	$786,727	$457,284	$29,946
Change In Account Payable	$786,727	$457,284	$29,946
Change In Prepaid Assets	$324,925	$39,575	$294,319
Other Non Cash Items	$362,308	$387,655	$800,969
Stock Based Compensation	$445,346	$77,887	$419,401
Gain Loss On Investment Securities	$-10,900	-	$29,000
Net Income From Continuing Operations	$-5,321,212	$-5,167,748	$-5,472,435
Net Long Term Debt Issuance	-	$3,296,182	$3,579,732
Long Term Debt Payments	-	$-146,912	$-328,088
Long Term Debt Issuance	-	$3,443,094	$3,907,820
Change In Other Working Capital	-	$85,881	$72,662
Proceeds From Stock Option Exercised	-	-	$0

Fetched: 2026-02-02